Spyre Therapeutics, Inc. announced the appointment of Sandra Milligan, M.D., J.D., President of Aspira Women's Health, to its Board of Directors. Prior to her current role at Aspira, Dr. Milligan served as the Head of Research and Development of Organon & Co. Previously, she served in key executive positions, including Senior Vice President and Head of Global Regulatory Affairs and Clinical Safety at Merck; Vice President of Product Development Regulatory at Genentech, Inc.; and important roles across legal and regulatory affairs at Amgen Inc. Dr. Milligan is being appointed as a successor to Russell Cox, whose Board term ended effective May 13, 2024.

Company express its gratitude for Russell's dedicated service as the Chairman of the Board. Jeffrey Albers, current member of the Board, has been appointed Chairman in connection with Russell's departure.